Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program.
We administered bupropion sustained-release (SR) in a pharmacist-managed outpatient smoking-cessation program. Patients were referred to the program by their primary care physician. All patients completed initial visit questionnaires, received behavioral counseling by a clinical pharmacist, and were provided educational materials on smoking cessation. Seventy-one patients received bupropion SR for treatment of nicotine dependence and were followed for 6 months. Point prevalence abstinence rates were 28.2% and 25.4% at 8 weeks and 6 months, respectively. The trend was toward lower cessation rates in patients with a documented psychiatric diagnosis at 6 months (p=0.064). Bupropion SR was fairly well tolerated, with the most common adverse effects being dry mouth and bad taste. The agent appears to have better success for smoking cessation in patients free of psychiatric comorbidities, but further research is required to support this finding.
Roth
M T
MT
Ambulatory Care Clinics, Durham Veterans Affairs Medical Center, North Carolina, USA.
Westman
E C
EC
D000368:Aged; D000553:Ambulatory Care / Q000706:statistics & numerical data; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use; D016009:Chi-Square Distribution; D015897:Comorbidity; D016001:Confidence Intervals; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016017:Odds Ratio; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D010595:Pharmacists / Q000706:statistics & numerical data; D012008:Recurrence; D012907:Smoking / Q000188:drug therapy / Q000453:epidemiology* / Q000523:psychology; D016540:Smoking Cessation / Q000523:psychology / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires
D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion